id: diabetes_exclusion_from_trials_to_tb_diabetes_comorbidity_management
name: Under-representation of People with Diabetes in TB Trials â†’ Evidence-Based Management
  of TB-Diabetes Comorbidity
from_node:
  node_id: diabetes_exclusion_from_trials
  node_name: Under-representation of People with Diabetes in TB Trials
to_node:
  node_id: tb_diabetes_comorbidity_management
  node_name: Evidence-Based Management of TB-Diabetes Comorbidity
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: 30% of TB trials explicitly exclude people with diabetes, and even trials
  allowing enrollment significantly under-enroll this population (9% enrolled vs 16%
  global prevalence)'
- 'Step 2: Diabetes affects immune function and TB treatment outcomes, but trials
  fail to capture these interactions'
- 'Step 3: Evidence gaps emerge regarding drug-drug interactions (rifampin and diabetes
  medications), adverse event profiles, and treatment efficacy in people with diabetes'
- 'Step 4: Clinical guidelines lack adequate evidence for managing TB-diabetes comorbidity'
- 'Step 5: People with diabetes experience suboptimal TB treatment outcomes due to
  lack of tailored, evidence-based approaches'
evidence:
  quality_rating: B
  n_studies: 40
  primary_citation: 'William Burman et al. 2025. "Representativeness and adverse event
    reporting in late-phase clinical trials for rifampin-susceptible tuberculosis:
    a systematic review.." *The Lancet. Infectious diseases*. https://doi.org/10.1016/S1473-3099(24)00597-8'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:07.117318'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: immune_function_impairment
  direction: strengthens
  strength: strong
  description: Diabetes impairs immune function, making this population critical for
    understanding TB treatment efficacy and adverse events
- name: drug_interactions
  direction: strengthens
  strength: strong
  description: Rifampin affects metabolism of diabetes medications, creating need
    for evidence on co-management that trials fail to provide
